Key facts
- This page summarizes Robert Barrow's Form 4 filing for Mind Medicine (MindMed) Inc. (MNMD).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 20 Aug 2024, 21:14.
Robert Barrow - 19 Aug 2024 Form 4 Insider Report for Mind Medicine (MindMed) Inc. (MNMD)
- Reporting relationship
- Chief Executive Officer, Director
- Issuer ticker
- MNMD
- Reported as of
- 19 Aug 2024
- Net transaction value
- +$6,215
- SEC form
- 4
- Accepted by SEC
- 20 Aug 2024, 21:14:04 UTC
- Prior SEC filing
- 25 Jun 2024
- Next SEC filing
- 25 Sep 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Mark Sullivan, Attorney-in-Fact for Robert Barrow
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Filing notes and source
Key filing fact
Robert Barrow filed Form 4 for Mind Medicine (MindMed) Inc. (MNMD) on 20 Aug 2024.
Change
- Previous filing in this sequence was filed on 25 Jun 2024.
- Current net transaction value: +$6,215.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MNMD
transaction
Common Shares
Purchase
- Transaction value
- $3,155
- Shares
- +500
- Change %
- +0.09%
- Price
- $6.31
- Shares after
- 565,043
- Date
- 19 Aug 2024
- Ownership
- Direct
- Footnotes
- F1
MNMD
transaction
Common Shares
Purchase
- Transaction value
- $3,060
- Shares
- +500
- Change %
- +0.09%
- Price
- $6.12
- Shares after
- 565,543
- Date
- 20 Aug 2024
- Ownership
- Direct
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The reported price in Column 4 is a weighted average purchase price. These shares were purchased in multiple transactions on August 19, 2024, at prices ranging from $6.29 to $6.33. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.